Leerink Partnrs Issues Positive Estimate for Pfizer Earnings

Pfizer Inc. (NYSE:PFE - Free Report) - Investment analysts at Leerink Partnrs lifted their Q3 2025 earnings estimates for shares of Pfizer in a report issued on Wednesday, December 18th. Leerink Partnrs analyst D. Risinger now expects that the biopharmaceutical company will post earnings per share of $1.11 for the quarter, up from their prior forecast of $1.05. The consensus estimate for Pfizer's current full-year earnings is $2.95 per share. Leerink Partnrs also issued estimates for Pfizer's Q4 2025 earnings at $0.66 EPS, FY2026 earnings at $3.10 EPS, FY2027 earnings at $3.03 EPS and FY2028 earnings at $2.67 EPS.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts' consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the previous year, the company posted ($0.17) earnings per share. The firm's revenue for the quarter was up 31.2% compared to the same quarter last year.

A number of other equities research analysts also recently issued reports on PFE. Truist Financial reduced their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday. Cantor Fitzgerald reiterated an "overweight" rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Wolfe Research began coverage on Pfizer in a report on Friday, November 15th. They set an "underperform" rating and a $25.00 price target on the stock. Bank of America reaffirmed a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Guggenheim reduced their target price on shares of Pfizer from $35.00 to $33.00 and set a "buy" rating on the stock in a report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Pfizer presently has a consensus rating of "Moderate Buy" and a consensus price target of $32.14.

Pfizer Trading Up 2.3 %

PFE stock traded up $0.59 during trading on Friday, reaching $26.36. 116,162,070 shares of the stock were exchanged, compared to its average volume of 39,035,680. The business has a 50 day moving average price of $26.82 and a 200-day moving average price of $28.18. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $149.38 billion, a price-to-earnings ratio of 35.62, a P/E/G ratio of 0.63 and a beta of 0.65. Pfizer has a 1 year low of $24.48 and a 1 year high of $31.54.

Institutional Trading of Pfizer

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Swiss National Bank increased its holdings in shares of Pfizer by 0.6% in the third quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company's stock valued at $486,762,000 after purchasing an additional 100,900 shares during the period. Charles Schwab Investment Management Inc. grew its position in Pfizer by 11.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock valued at $3,766,366,000 after buying an additional 12,864,343 shares during the last quarter. Empowered Funds LLC increased its stake in Pfizer by 80.9% in the 3rd quarter. Empowered Funds LLC now owns 508,256 shares of the biopharmaceutical company's stock valued at $14,709,000 after buying an additional 227,349 shares during the period. Addison Advisors LLC raised its position in Pfizer by 394.2% during the 3rd quarter. Addison Advisors LLC now owns 52,238 shares of the biopharmaceutical company's stock worth $1,512,000 after buying an additional 41,668 shares during the last quarter. Finally, KBC Group NV lifted its stake in shares of Pfizer by 26.0% in the 3rd quarter. KBC Group NV now owns 3,105,433 shares of the biopharmaceutical company's stock worth $89,872,000 after acquiring an additional 639,985 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the firm's stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares of the company's stock, valued at approximately $282,400. This represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.06% of the company's stock.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.53%. This is a boost from Pfizer's previous quarterly dividend of $0.42. Pfizer's payout ratio is currently 232.43%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.